In my humble opinion, and the reason for investing in OSL, the prospects are two-fold ( and entwined).
First, the obvious revenue of sales and it’s projection.
Second, the durability data of the patients’ wellbeing. That said, we know only approximately 5% of patients make the 5 year mark. So, each update on the durability data further validates the product.
The first sale as a milestone combined with the above 2 keys are essential toward what the company’s MC and status will be.
Time will tell, good entry point (imo).
Ann: OncoSil achieves first commercial sale, page-34
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $30.58M | |||
| Open | High | Low | Value | Volume |
| 0.9¢ | 1.0¢ | 0.9¢ | $99.72K | 11.05M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 6025000 | 0.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.9¢ | 2885714 | 3 |
View Market Depth
| Last trade - 13.12pm 22/07/2024 (20 minute delay) ? |
| OSL (ASX) Chart |